Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study | Zendy

Valentina Guarneri | Zendy; Antonio Frassoldati | Zendy; Alberto Bottini | Zendy; Katia Cagossi | Zendy; Giancarlo Bisagni | Zendy; Samanta Sarti | Zendy; Alberto Ravaioli | Zendy; Luigi Cavanna | Zendy; G Giardina | Zendy; Antonino Musolino | Zendy; Michael Untch | Zendy; Laura Orlando | Zendy; Fabrizio Artioli | Zendy; C. Boni | Zendy; Daniele Generali | Zendy; Patrizia Serra | Zendy; M. Bagnalasta | Zendy; Luca Marini | Zendy; Federico Piacentini | Zendy; Roberto D’Amico | Zendy; Pierfranco Conté | Zendy

Open Access

Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study

Author(s) -

Valentina Guarneri,

Antonio Frassoldati,

Alberto Bottini,

Katia Cagossi,

Giancarlo Bisagni,

Samanta Sarti,

Alberto Ravaioli,

Luigi Cavanna,

G Giardina,

Antonino Musolino,

Michael Untch,

Laura Orlando,

Fabrizio Artioli,

C. Boni,

Daniele Generali,

Patrizia Serra,

M. Bagnalasta,

Luca Marini,

Federico Piacentini,

Roberto D’Amico,

Pierfranco Conté

Publication year - 2012

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2011.39.0823

Subject(s) - lapatinib , medicine , trastuzumab , human epidermal growth factor receptor 2 , oncology , breast cancer , chemotherapy , epidermal growth factor receptor , cancer , gynecology

This is a noncomparative, randomized, phase II trial of preoperative taxane-anthracycline in combination with trastuzumab, lapatinib, or combined trastuzumab plus lapatinib in patients with human epidermal growth factor receptor 2 (HER2) -positive, stage II to IIIA operable breast cancer. The primary aim was to estimate the percentage of pathologic complete response (pCR; no invasive tumor in breast and axillary nodes).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research